Invitrogen Announces Opening of Hepatocyte Supply Facility in Warrington, UK
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Invitrogen has announced the opening of a new facility in Warrington, UK, which will supply freshly isolated human hepatocytes to researchers in Europe.
Human hepatocytes isolated from liver tissue are used for many biopharmaceutical applications, by researchers investigating liver diseases, and by scientists in the biotech and pharmaceutical sectors trying to predict a compound’s effect on enzyme metabolism in the liver. Many of these kinds of investigations are recommended by the US Food and Drug Administration (FDA) to minimize costly failures during clinical trials.
The new facility in Warrington will supplement the existing facility in North Carolina, USA, and will focus on the regular supply of fresh human hepatocytes to researchers in Europe. Fresh hepatocytes have a short shelf life, but they maintain key functions important for monitoring drug metabolism in vitro. A Rapid Alert™ email notification system has been developed in order to notify researchers of the availability of fresh cells.
“Hepatocytes are a well-established and high growth area of the global primary cells market. The opening of the new facility in Warrington will significantly support this rapidly growing area of hepatic biology in Europe.” said Nicolas Barthelemy, President, Life Technologies’ Cell Systems Division.
“Our new facility is part of Life Technologies ongoing commitment to serving the needs of cell biologists in Europe. The Warrington site will help us to ensure rapid access to high quality hepatocytes, for researchers investigating liver function and compound metabolism across a range of market sectors.” said Rob Brainin, Vice-President and General Manager, Invitrogen Hepatic Biology (CellzDirect) at Life Technologies.
Human hepatocytes isolated from liver tissue are used for many biopharmaceutical applications, by researchers investigating liver diseases, and by scientists in the biotech and pharmaceutical sectors trying to predict a compound’s effect on enzyme metabolism in the liver. Many of these kinds of investigations are recommended by the US Food and Drug Administration (FDA) to minimize costly failures during clinical trials.
The new facility in Warrington will supplement the existing facility in North Carolina, USA, and will focus on the regular supply of fresh human hepatocytes to researchers in Europe. Fresh hepatocytes have a short shelf life, but they maintain key functions important for monitoring drug metabolism in vitro. A Rapid Alert™ email notification system has been developed in order to notify researchers of the availability of fresh cells.
“Hepatocytes are a well-established and high growth area of the global primary cells market. The opening of the new facility in Warrington will significantly support this rapidly growing area of hepatic biology in Europe.” said Nicolas Barthelemy, President, Life Technologies’ Cell Systems Division.
“Our new facility is part of Life Technologies ongoing commitment to serving the needs of cell biologists in Europe. The Warrington site will help us to ensure rapid access to high quality hepatocytes, for researchers investigating liver function and compound metabolism across a range of market sectors.” said Rob Brainin, Vice-President and General Manager, Invitrogen Hepatic Biology (CellzDirect) at Life Technologies.
